EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated

Alan P Kozikowski iD, Joseph Neale

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01593 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Alan P Kozikowski und 1 weiteren Autor:innen. Beteiligte Einrichtung: Prostate Theranostics Inc., 1 Research Court, Suite 450, Rockville, Maryland 20850, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA), also known as GCPII, has emerged as a significant target in the diagnosis and treatment of prostate cancer. This perspective highlights the journey that led to the development of PSMA-targeted urea-based ligands, culminating in the clinical success of radiopharmaceuticals such as Pylarify and Pluvicto. Originating from research at Georgetown University, early PSMA inhibitors evolved through rational drug design starting from the neurotransmitter NAAG and a phosphonic acid derivative to simplified Glu-urea scaffolds with exceptional inhibitory activity. These ligands enabled the creation of both diagnostic and therapeutic radioligands, as well as emerging small molecule drug conjugates (SMDCs). Ongoing innovation includes bifunctional antigen targeting, alternative PSMA-binding motifs, and efforts to develop brain-penetrant GCPII inhibitors. This mini-perspective reveals how a collaborative chemistry/biology project not only redefined prostate cancer imaging and therapy but also opened new avenues for targeted cancer theranostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIHumansMaleChemistry, PharmaceuticalRadiopharmaceuticalsLigandsAntigens, SurfaceUreaAnimals

Substanzen

Glutamate Carboxypeptidase IIFOLH1 protein, humanRadiopharmaceuticalsLigandsAntigens, SurfaceUrea

Autor:innen und Institutionen

  • Prostate Theranostics Inc., 1 Research Court, Suite 450, Rockville, Maryland 20850, United States.
  • Department of Biology, Georgetown University, Washington, District of Columbia 20057, United States.

ORCID-Profile: Alan P Kozikowski

Zitieren

APA

Kozikowski, A. P., & Neale, J. (2025). How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01593

Vancouver

Kozikowski AP, Neale J. How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01593

BibTeX
@article{Kozikowski2025,
  author = {Kozikowski, Alan P and Neale, Joseph},
  title = {How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01593}
}
Kostenlos starten →